Overview
Sweden medical technology firm's Q1 net sales rose 10%, beating analyst expectations
Q1 EPS increased to SEK 1.15 from a loss last year
Company announced CFO transition during the quarter
Outlook
Company did not provide specific guidance for the current quarter or full year
Result Drivers
THORACIC SALES GROWTH - Thoracic sales increased by 27% in local currencies, supporting overall revenue growth
ABDOMINAL SALES GROWTH - Abdominal sales rose by 24% in local currencies, contributing to higher net sales
SERVICE SALES DECLINE - Services sales decreased by 10%, partially offsetting growth in other segments
Company press release: ID:nMFN6jk7TC
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
SEK 241 mln
SEK 238.25 mln (4 Analysts)
Q1 EPS
SEK 1.15
Q1 Net Income
SEK 36.30 mln
Q1 EBIT
SEK 31.90 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK337.00, about 12.3% above its April 23 closing price of SEK300.00
The stock recently traded at 63 times the next 12-month earnings vs. a P/E of 43 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)